Suppr超能文献

采用分次伽玛刀放射外科治疗初治 Koos 分级 IV 型前庭神经鞘瘤:回顾性单中心研究。

Management of treatment-naïve Koos grade IV vestibular schwannomas using hypofractionated Gamma Knife radiosurgery: a retrospective single-institution study.

机构信息

Department of Neurosurgery, Koç University School of Medicine, Türkiye Davutpasa Caddesi No:4, Istanbul, Zeytinburnu/İstanbul, 34010, Turkey.

Department of Neurosurgery, Gamma Knife Center, Koç University Hospital, Istanbul, Turkey.

出版信息

Neurosurg Rev. 2024 Nov 26;47(1):874. doi: 10.1007/s10143-024-03125-1.

Abstract

While single-fraction Gamma Knife radiosurgery (GKRS) has shown efficacy in managing vestibular schwannomas (VSs), some concerns have been raised regarding its safety profile, particularly in the context of hearing preservation. Hypofractionation has emerged as a promising approach to improving the safety profile. This retrospective, single-institution study evaluated patient outcomes following hypofractionated GKRS (hf-GKRS) for treatment-naïve Koos grade IV VSs. This study involved all patients with treatment-naïve Koos grade IV VSs who underwent hf-GKRS (3 or 5 fractions) between January 2018 and June 2021, with a follow-up period of ≥ 36 months. The outcomes assessed included local control (LC), the preservation of serviceable hearing as determined by the Gardner-Robertson hearing scale, and procedure-related adverse events. Twenty-nine patients (14 females, median age 49 years) were treated with three different dose regimens: 21 patients received 18 Gy in 3 fractions, 6 patients received 20 Gy in 5 fractions, and 2 patients received 25 Gy in 5 fractions. Prior to treatment, 13 patients (44.8%) had serviceable hearing, one (3.4%) presented with facial palsy, and four (13.8%) had trigeminal nerve dysfunction. The median tumor volume was 10.8 cm. During a median radiological follow-up period of 60 months (range, 36-78 months), LC was achieved in all patients. All 13 patients retained serviceable hearing at the last follow-up. Trigeminal nerve dysfunction occurred in one patient (3.4%), while another patient (3.4%) needed a ventriculoperitoneal shunt insertion due to new-onset hydrocephalus. No new-onset facial palsy was observed. hf-GKRS shows promise as an effective and safe primary or adjuvant treatment for Koos grade IV VSs with non-life-threatening or debilitating symptoms. Future studies with larger cohorts and extended follow-up periods are needed to validate these findings and to refine fractionation schemes.

摘要

单次分割伽玛刀放射外科(GKRS)已被证明在治疗前庭神经鞘瘤(VSs)方面具有疗效,但对于其安全性,尤其是在听力保护方面,存在一些担忧。分次治疗已成为提高安全性的一种有前途的方法。这项回顾性的单机构研究评估了接受分次伽玛刀放射外科(hf-GKRS)治疗的未经治疗的 Koos 分级 IV VSs 患者的预后。这项研究包括了所有在 2018 年 1 月至 2021 年 6 月期间接受 hf-GKRS(3 或 5 个分次)治疗的未经治疗的 Koos 分级 IV VSs 患者,随访期≥36 个月。评估的结果包括局部控制(LC)、Gardner-Robertson 听力量表评估的可保留听力以及与手术相关的不良事件。29 名患者(14 名女性,中位年龄 49 岁)接受了三种不同的剂量方案治疗:21 名患者接受 18 Gy/3 个分次,6 名患者接受 20 Gy/5 个分次,2 名患者接受 25 Gy/5 个分次。治疗前,13 名患者(44.8%)有可保留听力,1 名患者(3.4%)有面瘫,4 名患者(13.8%)有三叉神经功能障碍。肿瘤中位体积为 10.8 cm3。在中位影像学随访 60 个月(范围 36-78 个月)期间,所有患者均达到 LC。最后一次随访时,13 名患者均保留了可保留听力。1 名患者(3.4%)出现三叉神经功能障碍,另 1 名患者(3.4%)因新发脑积水需要行脑室-腹腔分流术。未观察到新发生的面瘫。hf-GKRS 作为一种有效的、安全的治疗 Koos 分级 IV VSs 的主要或辅助治疗方法,对于非危及生命或使人衰弱的症状具有广阔的应用前景。需要更大规模的队列和更长时间的随访来验证这些发现,并完善分次治疗方案。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验